Cargando…

Endothelial Cell Dysfunction and Hypoxia as Potential Mediators of Pain in Fabry Disease: A Human-Murine Translational Approach

Fabry disease (FD) is caused by α-galactosidase A (AGAL) enzyme deficiency, leading to globotriaosylceramide accumulation (Gb3) in several cell types. Pain is one of the pathophysiologically incompletely understood symptoms in FD patients. Previous data suggest an involvement of hypoxia and mitochon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klug, Katharina, Spitzel, Marlene, Hans, Clara, Klein, Alexandra, Schottmann, Nicole Michelle, Erbacher, Christoph, Üçeyler, Nurcan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607880/ https://www.ncbi.nlm.nih.gov/pubmed/37895103 http://dx.doi.org/10.3390/ijms242015422

Ejemplares similares

Dysregulation of Immune Response Mediators and Pain-Related Ion Channels Is Associated with Pain-like Behavior in the GLA KO Mouse Model of Fabry Disease
por: Spitzel, Marlene, et al.
Publicado: (2022)

X‐chromosomal inactivation patterns in women with Fabry disease
por: Wagenhäuser, Laura, et al.
Publicado: (2022)

Self-administered version of the Fabry-associated pain questionnaire for adult patients
por: Magg, Barbara, et al.
Publicado: (2015)

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease
por: Hofmann, Lukas, et al.
Publicado: (2017)

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
por: Loso, Jefferson, et al.
Publicado: (2018)

English version of the self-administered Fabry Pain Questionnaire for adult patients
por: Jovanovic, Ana, et al.
Publicado: (2020)

Increased Arterial Diameters in the Posterior Cerebral Circulation in Men with Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2014)

Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
por: Lenders, Malte, et al.
Publicado: (2016)

Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation
por: Pollmann, Solvey, et al.
Publicado: (2021)

Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y
por: Oder, Daniel, et al.
Publicado: (2016)

Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case–control study
por: Üçeyler, Nurcan, et al.
Publicado: (2013)

Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

Anderson–Fabry Disease: From Endothelial Dysfunction to Emerging Therapies
por: Stamerra, Cosimo A., et al.
Publicado: (2021)

Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly)
por: Lau, Kolja, et al.
Publicado: (2022)

Characterization of small fiber pathology in a mouse model of Fabry disease
por: Hofmann, Lukas, et al.
Publicado: (2018)

Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study
por: Wanner, Christoph, et al.
Publicado: (2022)

Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
por: Politei, Juan M., et al.
Publicado: (2016)

Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Cerebral hemodynamics and endothelial function in patients with Fabry disease
por: Segura, Tomás, et al.
Publicado: (2013)

Esomeprazole inhibits hypoxia/endothelial dysfunction–induced autophagy in preeclampsia
por: Gu, Shengyi, et al.
Publicado: (2022)

Endothelial Dysfunction Driven by Hypoxia—The Influence of Oxygen Deficiency on NO Bioavailability
por: Janaszak-Jasiecka, Anna, et al.
Publicado: (2021)

Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease
por: Köping, Maria, et al.
Publicado: (2017)

High-Dose Capsaicin for the Treatment of Neuropathic Pain: What We Know and What We Need to Know
por: Üçeyler, Nurcan, et al.
Publicado: (2014)

Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease
por: Liu, Dan, et al.
Publicado: (2018)

Translation of quality of life scale for pediatric patients with Fabry disease in Japan
por: Koto, Yuta, et al.
Publicado: (2022)

Effects of Endothelial Progenitor Cell-Derived Microvesicles on Hypoxia/Reoxygenation-Induced Endothelial Dysfunction and Apoptosis
por: Wang, Jinju, et al.
Publicado: (2013)

Neuroprotective Effects of Isosteviol Sodium in Murine Brain Capillary Cerebellar Endothelial Cells (cerebEND) After Hypoxia
por: Rösing, Nils, et al.
Publicado: (2020)

Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells
por: Do, Hyo-Sang, et al.
Publicado: (2020)

Distinct CholinomiR Blood Cell Signature as a Potential Modulator of the Cholinergic System in Women with Fibromyalgia Syndrome
por: Erbacher, Christoph, et al.
Publicado: (2022)

Hot topics in Fabry disease
por: Cairns, Tereza, et al.
Publicado: (2018)

Systematic review with meta-analysis: cytokines in fibromyalgia syndrome
por: Üçeyler, Nurcan, et al.
Publicado: (2011)

MDL-28170 Has No Analgesic Effect on CCI Induced Neuropathic Pain in Mice
por: Üçeyler, Nurcan, et al.
Publicado: (2010)

ALS or ALS mimic by neuroborreliosis—A case report
por: Wirsching, Isabelle, et al.
Publicado: (2019)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types
por: Welford, R W D, et al.
Publicado: (2018)

Diagnosis and Screening of Patients with Fabry Disease
por: Vardarli, Irfan, et al.
Publicado: (2020)

From the low-density lipoprotein receptor–related protein 1 to neuropathic pain: a potentially novel target
por: García-Fernández, Patricia, et al.
Publicado: (2021)

Renal Manifestations of Fabry Disease: A Narrative Review
por: Silva, Cassiano Augusto Braga, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a55dotqoe2spcltndb8384s99l